BioSphere Medical To Present At The Roth Capital Partners 22nd Annual OC Growth Stock Conference

BioSphere Medical, Inc. (NASDAQ: BSMD) – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – announced today that Martin Joyce, its executive vice president and chief financial officer, is scheduled to present at the 22 ^nd Annual Roth Capital Partners OC Growth Stock Conference on Monday, March 15, 2010 at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carton, Laguna Niguel in Dana Point, Calif.

The presentation will also be broadcast live over the Internet via the "Investors" page of the BioSphere Medical Web site at www.biospheremed.com. To listen to the live event, go to the Web site at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available at the Company's Web site for 30 days following the presentation.

About BioSphere Medical, Inc.

BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the use of its products for the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.

>To order reprints of this article, click here: Reprints